clinical trials

SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase IIb clinical trial for its medication to treat Tourette Syndrome (TS). This...

After Bright Minds Bioscience's (NASDAQ: DRUG) announcement that its quantitative EEG garnered positive results, the company stock shot up 91% Tuesday morning,  spiking to $6.18 from Monday's close of $3.23 per share. The recently-completed three-part Phase 1...

The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant layoffs.  Trials For Treatment-Resistant Depression atai is currently involved in two...

Numinus Wellness (OTCQX: NUMIF) expanded its clinical research capabilities into Phoenix, where the psychedelic-assisted therapy provider currently operates mental health clinics.  This is Numinus' third U.S.-based clinical trial research facility and fifth research site overall. It is set...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good Manufacturing Practices (GMP) facility in January 2023. In addition to psilocybin, the company intends to...

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD)....

After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial assessing low-dose, weekly intravenous (IV) ketamine infusion in participants with Major Depressive...

(Part four of a four-part series) See previous stories:  Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS' Published Results Psychedelics And Treatment-Resistant...

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022. Reunion’s president and CEO Greg Mayes stated that the company has consolidated as an independent company and is “well...

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. For the period, total cash was equivalent to $154.5 million -compared to $133.5 million as of December 31,...

Clinical-stage psychedelics company atai Life Sciences N.V. (NASDAQ: ATAI) reported its financial results for the quarter ended September 30, 2022 and shared business developments. Numbers show the company ended Q3 2022 with a cash position of $304.1 million, which combined with committed...

The state of Michigan is funding two major medical cannabis research projects to the tune of $20 million with tax revenue from the state’s recreational marijuana program, announced Michigan’s Marijuana Regulatory Agency (MRA). And There's No Shortage Of Cannabis Cash In...

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI) was...

Novavax, Inc (NASDAQ: NVAX) shares spiked nearly 32% in the after-hours and regular session on Thursday. What Happened: The Maryland-based biotechnology company said Thursday that its COVID-19 vaccine, NVX-CoV2373, was 96.4% effective “against mild, moderate and severe disease caused by the...